180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more
180 Life Sciences Corp (ATNF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.037x
Based on the latest financial reports, 180 Life Sciences Corp (ATNF) has a cash flow conversion efficiency ratio of -0.037x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.30 Million) by net assets ($445.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
180 Life Sciences Corp - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how 180 Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
180 Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 180 Life Sciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E-Lead Electronic Co Ltd
TW:2497
|
0.181x |
|
Moens Bank A/S
CO:MNBA
|
N/A |
|
Thye Ming Industrial Co Ltd
TW:9927
|
0.234x |
|
PRG Corporation Public Company Limited
BK:PRG
|
0.004x |
|
Kolibri Global Energy Inc. Common stock
NASDAQ:KGEI
|
0.033x |
|
Phoenix Tours International Inc
TW:5706
|
0.113x |
|
Oponeo.pl SA
WAR:OPN
|
-0.042x |
|
NIVIKA FASTIGHETER AB
F:Y5R
|
N/A |
Annual Cash Flow Conversion Efficiency for 180 Life Sciences Corp (2017–2024)
The table below shows the annual cash flow conversion efficiency of 180 Life Sciences Corp from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.25 Million | $-1.48 Million | -0.160x | -100.19% |
| 2023-12-31 | $-127.73K | $-10.92 Million | 85.508x | +8098.28% |
| 2022-12-31 | $11.34 Million | $-12.13 Million | -1.069x | -985.73% |
| 2021-12-31 | $39.32 Million | $-3.87 Million | -0.098x | +22.98% |
| 2020-12-31 | $30.29 Million | $-3.87 Million | -0.128x | -48.58% |
| 2019-12-31 | $38.57 Million | $-3.32 Million | -0.086x | -183.69% |
| 2018-12-31 | $-7.68 Million | $-789.23K | 0.103x | +2432.13% |
| 2017-12-31 | $112.83 Million | $-497.36K | -0.004x | -- |